Blueprint Medicines Co. to Post Q1 2025 Earnings of ($0.93) Per Share, Wedbush Forecasts (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Research analysts at Wedbush issued their Q1 2025 EPS estimates for Blueprint Medicines in a report issued on Thursday, May 2nd. Wedbush analyst D. Nierengarten anticipates that the biotechnology company will earn ($0.93) per share for the quarter. Wedbush currently has a “Outperform” rating and a $110.00 target price on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share. Wedbush also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.61) EPS and Q4 2025 earnings at ($0.43) EPS.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The firm’s revenue for the quarter was up 85.5% on a year-over-year basis. During the same period in the previous year, the company posted ($2.65) earnings per share.

A number of other brokerages also recently issued reports on BPMC. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research report on Thursday, May 2nd. Piper Sandler increased their price target on Blueprint Medicines from $78.00 to $104.00 and gave the company a “neutral” rating in a research report on Friday. Stifel Nicolaus boosted their price objective on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. SVB Leerink upgraded Blueprint Medicines from an “underperform” rating to a “market perform” rating and upped their price objective for the company from $50.00 to $97.00 in a research note on Monday. Finally, StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.31.

Blueprint Medicines Trading Down 0.9 %

BPMC opened at $106.25 on Monday. The firm has a market capitalization of $6.50 billion, a PE ratio of -22.14 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. Blueprint Medicines has a fifty-two week low of $43.89 and a fifty-two week high of $110.93. The company’s 50-day moving average is $91.77 and its 200 day moving average is $80.95.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, CEO Kate Haviland sold 12,464 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $1,130,360.16. Following the sale, the chief executive officer now directly owns 153,177 shares in the company, valued at approximately $13,891,622.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Blueprint Medicines news, CEO Kate Haviland sold 12,464 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $1,130,360.16. Following the transaction, the chief executive officer now directly owns 153,177 shares in the company, valued at approximately $13,891,622.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 25,073 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares in the company, valued at approximately $15,365,644. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,123 shares of company stock valued at $9,554,679. Corporate insiders own 3.88% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Blueprint Medicines during the 1st quarter valued at about $218,000. Principal Financial Group Inc. increased its position in Blueprint Medicines by 331.9% in the first quarter. Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company’s stock worth $5,945,000 after buying an additional 48,160 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Blueprint Medicines by 67.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,777 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 4,745 shares in the last quarter. Peregrine Capital Management LLC grew its position in shares of Blueprint Medicines by 2.0% during the first quarter. Peregrine Capital Management LLC now owns 93,583 shares of the biotechnology company’s stock valued at $8,877,000 after purchasing an additional 1,810 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of Blueprint Medicines by 8.5% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 36,929 shares of the biotechnology company’s stock valued at $3,503,000 after buying an additional 2,884 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.